Skip to main content
Top

02-05-2024 | Original Research Paper

Surface PD-1 expression in T cells is suppressed by HNRNPK through an exonic splicing silencer on exon 3

Authors: Jiayun Wang, Lingyan Yan, Xu Wang, Rong Jia, Jihua Guo

Published in: Inflammation Research

Login to get access

Abstract

Objective

Immunotherapy targeting programmed cell death 1 (PDCD1 or PD-1) and its ligands has shown remarkable promise and the regulation mechanism of PD-1 expression has received arising attention in recent years. PDCD1 exon 3 encodes the transmembrane domain and the deletion of exon 3 produces a soluble protein isoform of PD-1 (sPD-1), which can enhance immune response by competing with full-length PD-1 protein (flPD-1 or surface PD-1) on T cell surface. However, the mechanism of PDCD1 exon 3 skipping is unclear.

Methods

The online SpliceAid program and minigene expression system were used to analyze potential splicing factors involved in the splicing event of PDCD1 exon 3. The potential binding motifs of heterogeneous nuclear ribonucleoprotein K (HNRNPK) on exon 3 predicted by SpliceAid were mutated by site-directed mutagenesis technology, which were further verified by pulldown assay. Antisense oligonucleotides (ASOs) targeting the exonic splicing silencer (ESS) on PDCD1 exon 3 were synthesized and screened to suppress the skipping of exon 3. The alternative splicing of PDCD1 exon 3 was analyzed by semiquantitative reverse transcription PCR. Western blot and flow cytometry were performed to detect the surface PD-1 expression in T cells.

Results

HNRNPK was screened as a key splicing factor that promoted PDCD1 exon 3 skipping, causing a decrease in flPD-1 expression on T cell membrane and an increase in sPD-1 expression. Mechanically, a key ESS has been identified on exon 3 and can be bound by HNRNPK protein to promote exon 3 skipping. Blocking the interaction between ESS and HNRNPK with an ASO significantly reduced exon 3 skipping. Importantly, HNRNPK can promote exon 3 skipping of mouse Pdcd1 gene as well.

Conclusions

Our study revealed a novel evolutionarily conserved regulatory mechanism of PD-1 expression. The splicing factor HNRNPK markedly promoted PDCD1 exon 3 skipping by binding to the ESS on PDCD1 exon 3, resulting in decreased expression of flPD-1 and increased expression of sPD-1 in T cells.
Appendix
Available only for authorised users
Literature
4.
go back to reference Nielsen C, Ohm-Laursen L, Barington T, Husby S, Lillevang ST. Alternative splice variants of the human PD-1 gene. Cell Immunol. 2005;235(2):109–16.CrossRefPubMed Nielsen C, Ohm-Laursen L, Barington T, Husby S, Lillevang ST. Alternative splice variants of the human PD-1 gene. Cell Immunol. 2005;235(2):109–16.CrossRefPubMed
5.
go back to reference Song MY, Park SH, Nam HJ, Choi DH, Sung YC. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1. J Immunother. 2011;34(3):297–306.CrossRefPubMed Song MY, Park SH, Nam HJ, Choi DH, Sung YC. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1. J Immunother. 2011;34(3):297–306.CrossRefPubMed
6.
go back to reference Liu C, Jiang J, Gao L, Wang X, Hu X, Wu M, et al. Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways. Arthritis Res Ther. 2015;17:340.CrossRefPubMedPubMedCentral Liu C, Jiang J, Gao L, Wang X, Hu X, Wu M, et al. Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways. Arthritis Res Ther. 2015;17:340.CrossRefPubMedPubMedCentral
8.
go back to reference Bommarito D, Hall C, Taams LS, Corrigall VM. Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1. Clin Exp Immunol. 2017;188(3):455–66.CrossRefPubMedPubMedCentral Bommarito D, Hall C, Taams LS, Corrigall VM. Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1. Clin Exp Immunol. 2017;188(3):455–66.CrossRefPubMedPubMedCentral
9.
go back to reference Curran CS, Gupta S, Sanz I, Sharon E. PD-1 immunobiology in systemic lupus erythematosus. J Autoimmun. 2019;97:1–9.CrossRefPubMed Curran CS, Gupta S, Sanz I, Sharon E. PD-1 immunobiology in systemic lupus erythematosus. J Autoimmun. 2019;97:1–9.CrossRefPubMed
10.
go back to reference Falcone M, Fousteri G. Role of the PD-1/PD-L1 dyad in the maintenance of pancreatic immune tolerance for prevention of type 1 diabetes. Front Endocrinol. 2020;11:569.CrossRef Falcone M, Fousteri G. Role of the PD-1/PD-L1 dyad in the maintenance of pancreatic immune tolerance for prevention of type 1 diabetes. Front Endocrinol. 2020;11:569.CrossRef
11.
go back to reference Jia XH, Geng LY, Jiang PP, Xu H, Nan KJ, Yao Y, et al. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. J Exp Clin Cancer Res. 2020;39(1):284.CrossRefPubMedPubMedCentral Jia XH, Geng LY, Jiang PP, Xu H, Nan KJ, Yao Y, et al. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. J Exp Clin Cancer Res. 2020;39(1):284.CrossRefPubMedPubMedCentral
12.
go back to reference Luoma AM, Suo S, Williams HL, Sharova T, Sullivan K, Manos M, et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell. 2020;182(3):655-71.e22.CrossRefPubMedPubMedCentral Luoma AM, Suo S, Williams HL, Sharova T, Sullivan K, Manos M, et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell. 2020;182(3):655-71.e22.CrossRefPubMedPubMedCentral
13.
go back to reference Kobayashi M, Kawano S, Hatachi S, Kurimoto C, Okazaki T, Iwai Y, et al. Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren’s syndrome. J Rheumatol. 2005;32(11):2156–63.PubMed Kobayashi M, Kawano S, Hatachi S, Kurimoto C, Okazaki T, Iwai Y, et al. Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren’s syndrome. J Rheumatol. 2005;32(11):2156–63.PubMed
14.
go back to reference Chen RY, Zhu Y, Shen YY, Xu QY, Tang HY, Cui NX, et al. The role of PD-1 signaling in health and immune-related diseases. Front Immunol. 2023;14:1163633.CrossRefPubMedPubMedCentral Chen RY, Zhu Y, Shen YY, Xu QY, Tang HY, Cui NX, et al. The role of PD-1 signaling in health and immune-related diseases. Front Immunol. 2023;14:1163633.CrossRefPubMedPubMedCentral
15.
go back to reference Wan B, Nie H, Liu A, Feng G, He D, Xu R, et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol. 2006;177(12):8844–50.CrossRefPubMed Wan B, Nie H, Liu A, Feng G, He D, Xu R, et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol. 2006;177(12):8844–50.CrossRefPubMed
16.
go back to reference Wu H, Chen L, Zhou X, Wu Y, Yan Y, Zhu Y, et al. Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis. J Neuroimmunol. 2022;372: 577955.CrossRefPubMed Wu H, Chen L, Zhou X, Wu Y, Yan Y, Zhu Y, et al. Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis. J Neuroimmunol. 2022;372: 577955.CrossRefPubMed
18.
go back to reference Li D, Guo J, Jia R. Epigenetic control of cancer cell proliferation and cell cycle progression by HNRNPK via promoting exon 4 inclusion of histone code reader SPIN1. J Mol Biol. 2023;435(6): 167993.CrossRefPubMed Li D, Guo J, Jia R. Epigenetic control of cancer cell proliferation and cell cycle progression by HNRNPK via promoting exon 4 inclusion of histone code reader SPIN1. J Mol Biol. 2023;435(6): 167993.CrossRefPubMed
19.
go back to reference Liu M, Lin C, Huang Q, Jia J, Guo J, Jia R. SRSF3-mediated Ki67 exon 7-inclusion promotes head and neck squamous cell carcinoma progression via repressing AKR1C2. Int J Mol Sci. 2023;24(4):3872.CrossRefPubMedPubMedCentral Liu M, Lin C, Huang Q, Jia J, Guo J, Jia R. SRSF3-mediated Ki67 exon 7-inclusion promotes head and neck squamous cell carcinoma progression via repressing AKR1C2. Int J Mol Sci. 2023;24(4):3872.CrossRefPubMedPubMedCentral
22.
go back to reference Ito K, Sato K, Endo H. Cloning and characterization of a single-stranded DNA binding protein that specifically recognizes deoxycytidine stretch. Nucleic Acids Res. 1994;22(1):53–8.CrossRefPubMedPubMedCentral Ito K, Sato K, Endo H. Cloning and characterization of a single-stranded DNA binding protein that specifically recognizes deoxycytidine stretch. Nucleic Acids Res. 1994;22(1):53–8.CrossRefPubMedPubMedCentral
23.
go back to reference Crooke ST, Baker BF, Crooke RM, Liang X-H. Antisense technology: an overview and prospectus. Nat Rev Drug Discov. 2021;20(6):427–53.CrossRefPubMed Crooke ST, Baker BF, Crooke RM, Liang X-H. Antisense technology: an overview and prospectus. Nat Rev Drug Discov. 2021;20(6):427–53.CrossRefPubMed
25.
go back to reference Wang Z, Qiu H, He J, Liu L, Xue W, Fox A, et al. The emerging roles of hnRNPK. J Cell Physiol. 2020;235(3):1995–2008.CrossRefPubMed Wang Z, Qiu H, He J, Liu L, Xue W, Fox A, et al. The emerging roles of hnRNPK. J Cell Physiol. 2020;235(3):1995–2008.CrossRefPubMed
26.
go back to reference Khan M, Zhao Z, Arooj S, Fu Y, Liao G. Soluble PD-1: predictive, prognostic, and therapeutic value for cancer immunotherapy. Front Immunol. 2020;11:587460.CrossRefPubMedPubMedCentral Khan M, Zhao Z, Arooj S, Fu Y, Liao G. Soluble PD-1: predictive, prognostic, and therapeutic value for cancer immunotherapy. Front Immunol. 2020;11:587460.CrossRefPubMedPubMedCentral
27.
go back to reference Shin S, Seo H, Shin J, Park H, Lim D, Eom H, et al. Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response. Mol Ther. 2013;21(3):688–95.CrossRefPubMedPubMedCentral Shin S, Seo H, Shin J, Park H, Lim D, Eom H, et al. Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response. Mol Ther. 2013;21(3):688–95.CrossRefPubMedPubMedCentral
28.
go back to reference Liu C, Jiang J, Gao L, Wang X, Hu X, Wu M, et al. Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways. Arthrit Res Ther. 2015;17:340.CrossRef Liu C, Jiang J, Gao L, Wang X, Hu X, Wu M, et al. Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways. Arthrit Res Ther. 2015;17:340.CrossRef
29.
go back to reference Turunen J, Niemelä E, Verma B, Frilander M. The significant other: splicing by the minor spliceosome. Wiley Interdiscip Rev-RNA. 2013;4(1):61–76.CrossRefPubMed Turunen J, Niemelä E, Verma B, Frilander M. The significant other: splicing by the minor spliceosome. Wiley Interdiscip Rev-RNA. 2013;4(1):61–76.CrossRefPubMed
31.
go back to reference Wang Z, Qiu H, He J, Liu L, Xue W, Fox A, et al. The emerging roles of hnRNPK. J Cell Physiol. 2020;235(3):1995–2008.CrossRefPubMed Wang Z, Qiu H, He J, Liu L, Xue W, Fox A, et al. The emerging roles of hnRNPK. J Cell Physiol. 2020;235(3):1995–2008.CrossRefPubMed
32.
go back to reference Expert-Bezançon A, Le Caer J, Marie J. Heterogeneous nuclear ribonucleoprotein (hnRNP) K is a component of an intronic splicing enhancer complex that activates the splicing of the alternative exon 6A from chicken beta-tropomyosin pre-mRNA. J Biol Chem. 2002;277(19):16614–23.CrossRefPubMed Expert-Bezançon A, Le Caer J, Marie J. Heterogeneous nuclear ribonucleoprotein (hnRNP) K is a component of an intronic splicing enhancer complex that activates the splicing of the alternative exon 6A from chicken beta-tropomyosin pre-mRNA. J Biol Chem. 2002;277(19):16614–23.CrossRefPubMed
33.
go back to reference Bampton A, Gatt A, Humphrey J, Cappelli S, Bhattacharya D, Foti S, et al. HnRNP K mislocalisation is a novel protein pathology of frontotemporal lobar degeneration and ageing and leads to cryptic splicing. Acta Neuropathol. 2021;142(4):609–27.CrossRefPubMedPubMedCentral Bampton A, Gatt A, Humphrey J, Cappelli S, Bhattacharya D, Foti S, et al. HnRNP K mislocalisation is a novel protein pathology of frontotemporal lobar degeneration and ageing and leads to cryptic splicing. Acta Neuropathol. 2021;142(4):609–27.CrossRefPubMedPubMedCentral
34.
35.
go back to reference Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141–51.CrossRefPubMed Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141–51.CrossRefPubMed
36.
go back to reference Zamani M, Aslani S, Salmaninejad A, Javan M, Rezaei N. PD-1/PD-L and autoimmunity: a growing relationship. Cell Immunol. 2016;310:27–41.CrossRefPubMed Zamani M, Aslani S, Salmaninejad A, Javan M, Rezaei N. PD-1/PD-L and autoimmunity: a growing relationship. Cell Immunol. 2016;310:27–41.CrossRefPubMed
37.
go back to reference Ding H, Wu X, Wu J, Yagita H, He Y, Zhang J, et al. Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice. Clin Immunol (Orlando, Fla). 2006;118:258–67.CrossRef Ding H, Wu X, Wu J, Yagita H, He Y, Zhang J, et al. Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice. Clin Immunol (Orlando, Fla). 2006;118:258–67.CrossRef
39.
go back to reference Cooper TA. Use of minigene systems to dissect alternative splicing elements. Methods. 2005;37(4):331–40.CrossRefPubMed Cooper TA. Use of minigene systems to dissect alternative splicing elements. Methods. 2005;37(4):331–40.CrossRefPubMed
41.
go back to reference Coelho MB, Attig J, Bellora N, König J, Hallegger M, Kayikci M, et al. Nuclear matrix protein Matrin3 regulates alternative splicing and forms overlapping regulatory networks with PTB. Embo J. 2015;34(5):653–68.CrossRefPubMedPubMedCentral Coelho MB, Attig J, Bellora N, König J, Hallegger M, Kayikci M, et al. Nuclear matrix protein Matrin3 regulates alternative splicing and forms overlapping regulatory networks with PTB. Embo J. 2015;34(5):653–68.CrossRefPubMedPubMedCentral
Metadata
Title
Surface PD-1 expression in T cells is suppressed by HNRNPK through an exonic splicing silencer on exon 3
Authors
Jiayun Wang
Lingyan Yan
Xu Wang
Rong Jia
Jihua Guo
Publication date
02-05-2024
Publisher
Springer International Publishing
Published in
Inflammation Research
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-024-01887-4
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.